MIR103A1 (microRNA 103a-1; HGNC:31490, NCBI Gene 406895) at 5q34 encodes miR-103 — one of the miR-103/107 family whose members sit in the introns of the three pantothenate kinase genes: this locus in PANK3 at 5q34, the MIR103A2 paralog in PANK2 at 20p13, and miR-107 in PANK1 at 10q23.31. The family is a metabolism regulator — the insulin-sensitivity experiments' subject — and a widely used endogenous reference in circulating-miRNA assays.
Type 2 diabetes association studies; the reference-miRNA role in normalization
Gene Structure & Expression
Structure: One of three loci producing the near-identical miR-103/107 seeds, each hosted in a PANK gene intron — the pantothenate kinase hosts sit in coenzyme-A synthesis, a suggestive metabolic adjacency documented in the family's literature.
Expression: Broad, with the metabolic tissues the functional file; the family's stability profile underwrites its use as an endogenous reference alongside miR-191.
Molecular Function & Pathways
Insulin-sensitivity file: The miR-103/107 experiments showed gain-of-function in mice impairing insulin signaling through caveolin-1 down-regulation, and antagomir-mediated silencing improving insulin sensitivity — the metabolism paper the family is known for, acting on the INS-responsive program (see liver and adipose tissue).
Reference-miRNA role: The family's stable, abundant profile made miR-103 a standard normalization candidate in plasma and tissue assays — the methodological file it shares with miR-107.
Clinical & Therapeutic Significance
Diabetes: Association studies report miR-103 expression differences in type 2 diabetes cohorts; the antagomir experiments define the therapeutic concept on the insulin-sensitivity arm.
Metabolic disease broadly: The family recurs in obesity and fatty-liver panels — a metabolism miRNA more than an oncomiR, unlike most of this registry's microRNAs.